Clinical profile and outcome of children with haemophilia A: The Royal Hospital, Oman’s experience
Anood AlRawahi
Pediatrics Program, Oman Medical Speciality BoardMuscat, Oman
Orcid profileSearch for this author on
, Ibrahim AlGaithi
Consultant, Department of Pediatric Hematology/Oncology, Royal Hospital, Ministry of HealthMuscat, Oman
Orcid profileSearch for this author on
, Fatma Al Riyami
Medical Officer, Ministry of HealthMuscat, Oman
Orcid profileSearch for this author on
, Maather Al Abri
General Surgery Program, Oman Medical Specialty BoardMuscat, Oman
Orcid profileSearch for this author on
, Hajer Al Shukaili
General Foundation Program, Oman Medical Specialty BoardMuscat, Oman
Orcid profileSearch for this author on
and Abdulhakim Al Rawahi
Head of Research, Oman Medical Specialty BoardMuscat, Oman
Orcid profileSearch for this author on
Mar 19, 2025
About this article
Article Category: Clinical Research
Published Online: Mar 19, 2025
Page range: 23 - 28
DOI: https://doi.org/10.2478/jhp-2025-0003
Keywords
© 2025 Anood AlRawahi et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Clinical characteristics of children with haemophilia A treated at the Royal Hospital, Oman
| Number of persons, n (%) | 44 (100%) | 2 (4.5) | 29 (66) | 13 (29.5) |
| Joint bleeding | 3 (6.8) | 0 (0) | 3 (10.3) | 0 (0) |
| Muscle bleeding | 13 (29.5) | 0 (0) | 10 (34.5) | 3 (23.1) |
| Mucosal bleeding | 4 (9.1) | 1 (50) | 3 (10.3) | 0 (0) |
| Screening with positive family history | 20 (45.5) | 0 (0) | 12 (41.4) | 8 (61.5) |
| Post-circumcision bleeding | 5 (11.4) | 1 (50) | 2 (6.9) | 2 (15.4) |
| Intracranial bleeding | 1 (2.3) | 0 (0) | 1 (3.4) | 0 (0) |
| Post-operative bleeding | 2 (4.5) | 0 (0) | 1 (3.4) | 1 (7.7) |
| Joint involvement | 37 (84.1) | 1 (50) | 26 (89.7) | 10 (76.9) |
| At least one target joint | 10 (22.7) | 0 (0) | 7 (24) | 3 (23) |
| Muscle involvement | 17 (38.6) | 0 (0) | 12 (41.4) | 5 (38.5) |
| CNS involvement | 2 (4.5) | 0 (0) | 1 (3.4) | 1 (7.7) |
| Mucosal involvement | 5 (11.4) | 0 (0) | 5 (17.2) | 0 (0) |
| On-demand | 16 (36.4) | 1 (50) | 10 (34.5) | 5 (38.5) |
| Prophylaxis | 28 (63.6) | 1 (50) | 19 (65.5) | 8 (61.5) |
| Other treatments | 5 (11.4) | 1 (50) | 2 (6.8) | 2 (15.4) |
| Inhibitor development | 6 (13.6) | 0 (0) | 3 (10.3) | 3 (23.1) |
| CNS complications | 1 (2.3) | 0 (0) | 1 (3.4) | 0 (0) |
| Joint arthropathy | 24 (54.5) | 0 (0) | 17 (58.6) | 7 (53.8) |
| ABR, mean ± SD | 4.4 ± 0.4 | 1.8 ± 2.3 | 4.6 ± 0.4 | 4.6 ± 8.6 |